Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

OSR Holdings (NASDAQ: OSRH) appoints Vaximm co-founder Dr. Andreas Niethammer as CEO

Dr. Andreas Niethammer will lead Vaximm’s immuno-oncology growth, focusing on oral T-cell vaccines and strategic collaborations for advanced solid tumors, including renal cell carcinoma.

Summary by stocktitan.net
Effective Dec 1, 2025. Vaximm develops oral T-cell immunotherapies; lead VXM01 targets VEGFR-2. Strategy adds viral oncolysis with Phase 2a proof-of-concept.

9 Articles

The Chandler ArizonanThe Chandler Arizonan
+7 Reposted by 7 other sources
Center

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

BELLEVUE, Wash., Nov. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm AG's Chief Medical Offer and scientific co-founder, as Chief Executive Officer (CEO), effective December 1, 2025. Vaximm…

·Chandler, United States
Read Full Article
stocktitan.netstocktitan.net

OSR Holdings (NASDAQ: OSRH) appoints Vaximm co-founder Dr. Andreas Niethammer as CEO

Effective Dec 1, 2025. Vaximm develops oral T-cell immunotherapies; lead VXM01 targets VEGFR-2. Strategy adds viral oncolysis with Phase 2a proof-of-concept.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Friday, November 14, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Bellevue, Washington icon

Bellevue, Washington

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal